Pharmacological Interventions in ASD: A review of pharmacological treatment options for symptoms associated with autism, such as aggression and hyperactivity.

• DOI: 10.22533/at.ed.15938923231010

• Palavras-chave: Autism Spectrum Disorder; pharmacological interventions; antipsychotic medications; stimulants; challenging behaviors.

• Keywords: Autism Spectrum Disorder; pharmacological interventions; antipsychotic medications; stimulants; challenging behaviors.

• Abstract: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by a diverse range of symptoms, including social communication challenges and repetitive behaviors. Pharmacological interventions play a vital role in managing specific ASD-related symptoms, with a focus on addressing challenging behaviors such as aggression and hyperactivity. This review explores the landscape of pharmacological interventions in ASD, categorizing them into antipsychotic medications, stimulants, and other pharmacological agents. Antipsychotic medications, exemplified by risperidone and aripiprazole, demonstrate efficacy in reducing aggression and irritability in individuals with ASD, but concerns about side effects and the necessity for individualized treatment plans exist. Stimulant medications, originally designed for Attention-Deficit/Hyperactivity Disorder (ADHD), show potential in managing hyperactivity and attention problems, albeit with considerable variability in responses among individuals. Furthermore, other pharmacological agents, including SSRIs, naltrexone, melatonin, and GABA agonists, offer alternative strategies to address specific ASD-related symptoms. The discussion encompasses their potential benefits while emphasizing the need for personalized treatment plans and vigilant monitoring of individual responses. The broader implications of pharmacological interventions in ASD involve ethical considerations and concerns about long-term effects on growth and development. A collaborative approach involving healthcare providers, caregivers, and individuals with ASD is essential for treatment decision-making and ongoing monitoring. In conclusion, pharmacological interventions in ASD present a complex landscape, offering both promise and challenges. A holistic treatment approach that combines behavioral and pharmacological strategies, while respecting individual needs, holds the potential to enhance the quality of life for individuals with ASD